The use of CDK4/6 inhibitor Ibrance (palbociclib), in combination with either Aromasin (exemestane), which is an estrogen modulator, or the chemotherapy Faslodex (fulvestrant), shows promise for patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer, [More]
Professors Joseph Gligorov, Yen-Shen Lu, Chris Twelves and Dr Reshma Mahtani meet in San Antonio at the San Antonio Breast Cancer Symposium 2018 annual meeting for an educational breast cancer panel discussion. Their talk covers [More]
Joyce O’Shaughnessy, MD, provides her perspective on optimizing chemotherapy use in patients with metastatic breast cancer.
Joyce O’Shaughnessy, MD, and Mark Pegram, MD, describe how chemotherapy has improved in the past few decades so that patients with metastatic breast cancer in the modern era of treatment are receiving more lines of [More]
Erica Mayer, MD, MPH, and Nancy Lin, MD, describe the many new treatments being studied for metastatic breast cancer patients. Learn more at
My Oncologist did not want to waste time, and only a few days after finding out about my recurrence, I underwent my first round of chemotherapy :Adriamycin & Taxotere for my breast metastasis to the [More]
Mark Pegram, MD, and Joyce O’Shaughnessy, MD, discuss the historic perspective on chemotherapy and sequential single-agent use of chemotherapy for advanced breast cancer.
Fast forward to today, after 6 rounds of chemo (sorry I haven’t had time to edit and upload my vlogs but I’ll definitely go back in time later), I finally receive my CT scan results [More]
Laura Magill’s September 4, 2011 testimony of invasive metastatic breast cancer healed without chemotherapy, radiation, surgery – how she used intravenous therapies (I.V.), hyperbaric oxygen therapy (HBOT) and supplements administered at Pacific Medical Center of [More]